News
-
2025.07.03
RESEARCHES
Establishment of a Basic Policy on the Handling of Genomic and Its Analytical Data of Blood Samples, iPS Cell Stocks and Their Differentiated Cells
(With Consideration for the Protection of Donor Privacy) - 2025.06.13 RESEARCHES Notice of Amendment to Terms and Conditions of the Usage License for a Healthy Human-derived iPS Cell Line for Research (CFiS Series)
-
2025.03.26
RESEARCHES
iPS Cell Stock Collaboration Agreement Signing Between Mayo Clinic and CiRA Foundation
- 2025.01.14 RESEARCHES Notice on our iPS cell stock “QHJI01s04”
-
2024.06.10
OTHER
New Facility for Clinical Cell Manufacturing Named
"Yanai Facility for my iPS Cell Therapy" -
2024.03.19
RESEARCHES
Terumo Blood and Cell Technologies partners with CiRA Foundation to develop automated iPS cell manufacturing
- 2024.02.22 RESEARCHES Registration of iPS cell stock (QHJI strain) for clinical use as a U.S. Drug Master File
- 2024.01.18 RESEARCHES CiRA_F and CIRM Sign Agreement for Widespread Use of iPS Cell Stock
- 2023.12.26 RESEARCHES Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson's Disease in the United States
-
2023.06.14
RESEARCHES
Provision of HLA Genome-edited iPS Cell Stock for Clinical Use